

1 **Soraphen A: a broad-spectrum antiviral natural product**

2 **with potent anti-hepatitis C virus activity**

3
4 George Koutsoudakis¹, Inés Romero-Brey^{2*}, Carola Berger^{2*}, Gemma Pérez-Vilaró¹,
5 Paula Monteiro Perin^{3,4}, Florian Wolfgang Rudolf Vondran^{4,5}, Markus Kalesse⁶, Kirsten
6 Harmrolfs⁷, Rolf Müller⁷, Javier P. Martinez⁸, Thomas Pietschmann³, Ralf
7 Bartenschlager^{2,9}, Mark Brönstrup⁶, Andreas Meyerhans^{8,10}, Juana Díez^{1†}

8
9 *equally contributed to this work

10 † Corresponding author

11
12 ¹Molecular Virology Group, Department of Experimental and Health Sciences,
13 Universitat Pompeu Fabra, Barcelona, Spain.

14 ²Department of Infectious Diseases, Molecular Virology, Heidelberg University,
15 Heidelberg, Germany.

16 ³TWINCORE - Institute of Experimental Virology, Centre for Experimental and
17 Clinical Infection Research, Hannover, Germany.

18 ⁴German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig,
19 Germany.

20 ⁵ReMediES, Department of General, Visceral and Transplantation Surgery, German
21 Centre for Infection Research Hannover Medical School, Hannover, Germany.

22 ⁶Department of Chemical Biology, Helmholtz Centre for Infection Research,
23 Braunschweig, Germany.

24 ⁷Helmholtz Institut für Pharmazeutische Forschung Saarland, Saarbrücken, Germany.

1 ⁸Infection Biology Group, Department of Experimental and Health Sciences,
2 Universitat Pompeu Fabra, Barcelona, Spain.

3 ⁹German Centre for Infection Research (DZIF), partner site Heidelberg, Germany.

4 ¹⁰Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

5

6 Correspondence should be addressed to:

7 Juana Díez, PhD

8 Molecular Virology Group

9 Department of Experimental and Health Sciences

10 Universitat Pompeu Fabra

11 Doctor Aiguader 88, 08003, Barcelona, Spain

12 Tel: 00-34-933160862; Fax: 00-34-933160901

13 e-mail: juana.diez@upf.edu

14

15 **Total electronic word count: 5,991 Figures: 8**

16

17 **Abbreviations used in this manuscript:**

18 HCV, hepatitis C virus; HIV, human immunodeficiency virus; VLDL, very low density

19 lipoprotein; LDL, low density lipoprotein; ACC, acetyl CoA carboxylase; SorA,

20 Soraphen A; DMVs, double membrane vesicles; HCVcc, cell-culture-derived HCV;

21 TOFA, 5-(Tetradecyloxy)-2-furoic acid; MOI, multiplicity of infection; ; EC₅₀, half

22 maximal effective concentration; CC₅₀, half maximal cytotoxic concentration; SI,

23 selectivity index; 2'-C-Met, 2'-C-methyladenosine; PHHs, primary human hepatocytes;

24 TCID₅₀, Tissue culture infectious dose 50; SGR, subgenomic replicon; HCVpp, HCV

25 pseudoparticles; IRES, internal ribosomal entry site; EM, electron microscopy; DMVs,

1 double-membrane vesicles; FDA, Food and Drug Administration; DAAs, direct-acting
2 antivirals; Sol, Solubility; JFH1, Japanese fulminant hepatitis 1; EMCV,
3 encephalomyocarditis virus; DMSO, dimethyl sulfoxide; UTR, untranslated region.

4
5 **Keywords:** HCV/HIV co-infection, HCV replication inhibitor, lipid metabolism, broad-
6 spectrum antiviral, natural product.

7
8 **Conflict of interest:** The authors who have taken part in this study declared that they do
9 not have anything to disclose regarding funding or conflict of interest with respect to
10 this manuscript.

11
12 **Authors Contributions:**

13 GK designed the study and prepared the manuscript. GK, GPV, IRB, CB, PMP, FWRV,
14 KH performed the experiments and analysed the data. JM, TP, RB, RM, MK, MB and
15 AM supervised parts of this study. JD supervised all aspects of this study and
16 contributed to manuscript preparation. All authors contributed to the interpretation and
17 discussion of the results, as well as to the revision of the manuscript.

1 **Abstract**

2

3 **Background & Aims:** Co-infections by the hepatitis C virus (HCV) and human
4 immunodeficiency virus (HIV) represent a significant challenge for treatment due to the
5 necessity of combining diverse antiviral compounds that often leads to complex drug-
6 drug interactions. Soraphen A (SorA) is a myxobacterial metabolite that inhibits the
7 acetyl-CoA carboxylase, a key enzyme in lipid biosynthesis. We have previously
8 identified SorA to efficiently inhibit HIV. The aim of the present study was to evaluate
9 the capacity of SorA and analogues to inhibit HCV infection.

10 **Methods:** SorA inhibition capacity was evaluated *in vitro* using cell-culture derived
11 HCV, HCV pseudoparticles and subgenomic replicons. Infection studies were
12 performed in the hepatoma cell line Huh7/Scr and in primary human hepatocytes. The
13 effects of SorA on membranous web formation were analyzed by electron microscopy.

14 **Results:** SorA potently inhibits HCV infection at nanomolar concentrations. Obtained
15 EC₅₀ values were 0.70 nM with a HCV reporter genome, 2.30 nM with wild-type HCV
16 and 2.52 nM with subgenomic HCV replicons. SorA neither inhibited HCV RNA
17 translation nor HCV entry, as demonstrated with subgenomic HCV replicons and HCV
18 pseudoparticles, suggesting an effect on HCV replication. Consistent with this, evidence
19 was obtained that SorA interferes with formation of the membranous web, the site of
20 HCV replication. Finally, a series of natural and synthetic SorA analogues helped to
21 establish a first structure-activity relationship.

22 **Conclusions:** SorA has a very potent anti-HCV activity. Since it also inhibits HIV,
23 SorA is a promising candidate for the development of simplified treatments of
24 HCV/HIV co-infection.

25

1 **Introduction**

2

3 The hepatitis C virus (HCV) and the human immunodeficiency virus (HIV) have
4 infected around 170 million and 35 million individuals worldwide, respectively. Due to
5 overlapping acquisition modes, the number of individuals co-infected with HCV and
6 HIV has risen up to 7 million [1]. In developed countries, HIV-infected individuals who
7 inject drugs and HIV-infected men who have sex with men comprise the majority of
8 HCV/HIV co-infected patients. Amongst the latter, multiple HCV outbreaks and
9 reinfections have recently been described [2].

10

11 HCV mono-infection and HCV/HIV co-infection treatment(s) have changed
12 dramatically in the era of Direct-Acting Antivirals (DAAs) [3]. Currently approved
13 DAAs include NS3-4A protease inhibitors (telaprevir, boceprevir and simeprevir)
14 NS5A inhibitors (daclatasvir and ledipasvir) and the NS5B polymerase inhibitor
15 sofosbuvir. While regimens containing these DAAs have brought major progress,
16 several limitations remained. First, the therapeutic efficiency towards the different HCV
17 genotypes varies. Second, although some DAAs present high barrier to resistance (i.e.
18 sofosbuvir), in general this property is low. Third, the deleterious interactions between
19 some anti-HCV and anti-HIV drugs and the associated liver toxicities [4]. Forth,
20 therapy costs are extremely high and represent a significant financial burden even for
21 countries with developed economies .Treatment simplifications that may include broad-
22 spectrum antiviral drugs targeting both viruses could help in solving some of these
23 issues.

24

25 Due to their genome simplicity, viruses rely on a network of host-cell factors to multiply.

1 Host-targeting drugs inhibiting cellular factors required for HCV to replicate are already
2 in clinical trials. These include the cyclophilin inhibitors alisporivir and SCY-635, the
3 miR-122 inhibitor miravirsen and the SR-B1 receptor blocker ITX-5061 [5, 6]. Since
4 some host factors are exploited by different viruses, conceptually, it would be possible
5 to inhibit several viruses by targeting shared host factors. Given the genetic stability of
6 the host, the development of such broad-spectrum antivirals would have the additional
7 advantage of rendering selection of drug resistant virus mutants less likely, a major
8 problem of conventional drugs that target viral proteins [7]. Initial efforts in this
9 direction are showing promising results [8, 9]. Predicted good targets for the
10 development of antiviral drugs that act on HCV and HIV are the proteins that modulate
11 the lipid metabolism. HCV particles that circulate in the blood of infected patients are
12 associated with very low and low density lipoproteins (VLDL and LDL), resembling the
13 so-called lipo-viral particle. Lipids have been shown to play an important role during
14 entry (apolipoproteins), replication (fatty acids) and during budding and egress (VLDLs
15 and LDLs) [10]. Thus, the HCV life cycle is intimately linked to intracellular
16 membranes and host-cell lipid synthesis. The role of lipids in the HIV life cycle is also
17 quite profound. HIV virion assembly, encapsidation and budding from the cell surface
18 of the infected cell require a lipid milieu enriched in cholesterol and
19 phosphatidylinositol-4,5-bisphosphate [11]. In addition, modifiers of the cellular lipid
20 metabolism have been shown to affect HIV propagation [12].

21

22 By screening a library of secondary metabolites produced by *Myxobacteria*, we
23 discovered recently that soraphens possess anti-HIV activities [13]. Soraphens are a
24 group of polyketide natural products that have been first identified due to their potent
25 antifungal activity [14] and more recently received much attention due to their anti-

1 cancer [15], insulin-sensitizing [16] and immunoregulatory functions [17]. Soraphens
2 mediate their function via inhibition of acetyl-CoA carboxylase enzyme (ACC) [18] that
3 plays a key role in the cellular homeostasis of fatty acids. In humans exist two ACC
4 isoforms (ACC1 and ACC2, a cytosolic and mitochondrial isoform, respectively) that are
5 encoded by separate genes [19]. As soraphens are known to alter the lipid metabolism of
6 treated cells [20], and the HCV life cycle critically depends on lipids [10], we tested
7 soraphen A (SorA) for its anti-HCV activity. Here, we show that SorA is a highly potent
8 HCV inhibitor that is active in the low nanomolar range. It exerted its activity, at least in
9 part, via interfering with the formation of double membrane vesicles (DMVs) that are the
10 sites of HCV replication. A structure/activity analysis conducted in this study suggested
11 options for structural modifications to optimize the pharmacological properties of SorA
12 towards a strategy for a potent anti-HCV/HIV clinical drug development.

13

14

15 **Materials and Methods**

16

17 A detailed description of the methods used in this manuscript is provided in the
18 *Supplementary Material* section.

19

20

21

22

23

24

25

1 **Results**

2

3 *SorA inhibits HCVcc infection*

4

5 We have recently identified SorA as HIV inhibitor [13]. To assess the inhibitory effects
6 of SorA (Fig. 1A) on HCV infection we used the HCV cell-culture (HCVcc) system
7 [23-25]. Unless otherwise stated, we used the Huh7/Scr and the Huh7/Lunet [26] cells,
8 which are highly permissive for HCV propagation *in vitro*. Our experiments were
9 performed in the context of genotype 2a (Jc1 chimera [27]) HCVcc virus. To facilitate
10 the quantification of infection, we used the bicistronic Jc1 luciferase reporter construct,
11 designated Luc-Jc1 [28]. Cell viability was monitored in parallel by a commercial ATP
12 assay [29]. The commercial ACC inhibitor 5-(Tetradecyloxy)-2-furoic acid (TOFA),
13 which has been previously described to inhibit HCV replication [30], was used for
14 comparison. The NS3-4A serine protease inhibitor VX-950 [31], a known HCV
15 replication inhibitor, was used as positive control. As shown in Fig. 1B, Luc-Jc1 virus
16 infection in Huh7/Scr cells (at an MOI of 0.03 TCID₅₀/cell) was strongly inhibited by
17 SorA at concentrations in the 1-10 nM range. Viability assays show no toxicity of the
18 compounds up to 10 μM. The half maximal effective concentration (EC₅₀) for SorA was
19 estimated 0.70 nM [the half maximal cytotoxic concentration (CC₅₀): ~98.52 μM, and
20 the selectivity index (SI): 140,742], as compared with an EC₅₀ of 1.01 μM for TOFA
21 [CC₅₀: ~33.87 μM, SI: 33.53] and an EC₅₀ of 18.92 nM for VX-950 [CC₅₀: ~94.51 μM,
22 SI: 4,995] in this assay. To demonstrate the specific inhibitory activity of SorA against
23 HCV at a higher MOI, Jc1 virus (which does not carry a reporter gene) was challenged
24 in similar experiments with increasing doses of SorA. As shown in Fig. 1C, SorA also
25 inhibited Jc1 infection at an MOI of 1 TCID₅₀/cell in an equipotent manner. The EC₅₀

1 value was 2.30 nM [$CC_{50} \geq 10 \mu\text{M}$, $SI \geq 4,357$]. A 2'-modified nucleoside analog (2'-C-
2 methyladenosine, 2'-C-Met) [32] was used as a positive control [EC_{50} : 0.101 μM , CC_{50} :
3 12.42 μM , SI : 122.97].
4

5 Although Huh7 cells are a well-accepted cell culture model for HCV infection studies,
6 these cells might present differences in lipid metabolism compared to primary human
7 hepatocytes (PHHs). To further corroborate our findings in a more natural system,
8 PHHs were inoculated with Jc1 virus (at an MOI of 0.2 $TCID_{50}/\text{cell}$) in the presence of
9 SorA or VX-950. 24 and 48h post-infection cell culture supernatants were harvested and
10 the amount of virus production by the PHHs was quantified by an endpoint dilution
11 assay ($TCID_{50}$). As shown in Fig. 1D, Jc1 infection of PHHs was also inhibited by
12 SorA. Similar to Huh7/Scr cells, SorA was not toxic to PHHs up to 10 μM (data not
13 shown). Conclusively, our *in vitro* results using human hepatoma carcinoma-derived
14 cell line Huh7/Scr as well as PHHs demonstrate that SorA is a very potent non-toxic
15 inhibitor of HCV infection.
16

17 *SorA inhibits HCV subgenomic replicons*

18

19 To investigate the impact of SorA in HCV RNA translation and/or replication, we
20 transfected Huh7/Scr cells with a subgenomic JFH1 luciferase replicon (SGR-JFH1,
21 Fig. 2A, top) [33]. These HCV subgenomes do not contain structural proteins and
22 therefore cannot sustain HCV particle production. However, they possess the ability to
23 replicate autonomously in cell culture, rendering them powerful tools for HCV
24 translation and replication studies. As shown in Fig. 2A, SorA inhibits HCV RNA
25 translation and/or replication as deduced by the reduced luciferase values. The EC_{50} for

1 SorA was estimated to be 2.52 nM [CC₅₀: 75.78 μM, SI: 30,071], while EC₅₀ values for
2 the control compounds TOFA and VX-950 were estimated to be 72.55 nM [CC₅₀: 27.2,
3 SI: 374.91] and 1.55 nM [CC₅₀: 43.6 μM, SI: 28,129], respectively. To expand our
4 analyses in other genotypes we treated with SorA a stable Huh7 cell line which harbors
5 the Con1 subgenomic replicon that belongs to the 1b genotype (I₃₈₉/NS3-3'/LucUbiNeo-
6 ET [34], Supplementary Fig. 1A). As shown in Supplementary Fig. 1B, SorA inhibited
7 potently the replication of the Con1 subgenomic replicon in a nanomolar range (0.01-
8 1.0 nM), confirming an inhibitory capacity of SorA against the 1b genotype as well.

9

10 *SorA does not inhibit HCV entry*

11

12 Infection of hepatocellular carcinoma-derived cell lines with HCV pseudoparticles
13 (HCVpp) is a well-established system to investigate HCV entry and neutralization [35].
14 HCVpp are formed by incorporation of the full-length HCV glycoproteins E1 and E2
15 into the envelope of lenti- or retroviral core particles. To test the effect of SorA on HCV
16 entry we used HCVpp which carry glycoproteins (genotype 2a, isolate J6CH) identical
17 to those of the Luc-Jc1 virus. The results are presented in Fig. 2B and show that SorA
18 does not inhibit HCVpp infection at 5 μM concentration while dasatinib [36], a known
19 HCV entry inhibitor, showed potent inhibitory HCVpp capacity at the same
20 concentration. This demonstrates that SorA does not exert its inhibitory capacity in the
21 entry step and in combination with previous results it narrows down its inhibitory
22 activity to translation and/or replication. Similar to the HCVcc experiments, the
23 compounds were found to be non-toxic at a concentration of 5 μM in Huh7/Scr cells.

24

25

1 *SorA does not inhibit HCV RNA translation*

2

3 To investigate a putative inhibitory effect of SorA on HCV RNA translation we used a
4 replication incompetent SGR-JFH1 which harbors a Δ GDD deletion in the NS5B
5 protein, thus abolishing its replication activity [37]. In this subgenomic reporter system
6 the expression of the *Firefly luciferase* gene is driven by the internal ribosomal entry
7 site (IRES) of HCV and thus, reporter gene expression is attributed solely to HCV-IRES
8 mediated translation. As shown in Fig. 2C, neither SorA, nor TOFA, nor VX-950
9 presented an effect on HCV IRES-driven luciferase expression. As a positive control,
10 puromycin, a drug that causes premature chain termination during translation, almost
11 completely inhibited HCV RNA translation as expected (Supplementary Fig. 2). Taken
12 together, these results point to a role of SorA in HCV RNA replication.

13

14 *Fatty acids add-back rescues HCV replication in SorA treated cells*

15

16 ACC is a biotin-dependent enzyme that catalyzes the formation of acetyl-CoA to
17 malonyl-CoA, which is the rate-limiting step for the biosynthesis of fatty acids [38].
18 Since HCV possesses an intimate connection to fatty acids and lipids [10] we sought to
19 rescue HCV replication in SorA treated cells by fatty acids or lipids add-back during
20 infection. As shown in Fig. 3A, addition of palmitic, myristic or lauric acids to the
21 culture medium simultaneously to infection partially restored HCV replication in a dose
22 dependent-manner, while addition of sphingomyelin or phosphatidylserine did not exert
23 any beneficial effect for HCV replication. Cell viability data for these assays are shown
24 in Fig. 3B.

25

1 *SorA affects the formation of double-membrane vesicles*

2

3 HCV RNA replication occurs in close association with rearranged intracellular
4 membranes forming a vesicular network that has been designated membranous web
5 [39]. It consists predominantly of double-membrane vesicles (DMVs) [40], which
6 contain viral proteins, replicating viral RNA and altered intracellular membranes [41].
7 To study the effect of SorA on DMVs' formation we used electron microscopy (EM) in
8 two different experimental systems. First, we analyzed DMVs formation in stable T7
9 RNA polymerase-expressing Huh7-Lunet/T7 cells, transfected with a plasmid encoding
10 the proteins NS3 to NS5B (NS3-5B) of the JFH1 isolate under control of the T7
11 promoter (Fig. 4A-C). As previously shown, expression of the NS3-5B polyprotein
12 induces a membranous web that is morphologically indistinguishable from the one
13 found in HCV-infected cells [40] (Fig. 4D-F). Importantly, treatment of transfected
14 cells with SorA reduced in a statistically significant manner the DMVs number (Fig.
15 4G). This result is consistent with the observed inhibition of HCV replication by this
16 compound. To validate this finding in a HCV infectious system, we repeated the
17 analysis by using cells that had been transfected with replication-competent Jc1 RNA
18 and treated with SorA for 96h (Fig. 5). Abundance of HCV proteins was not affected at
19 1 nM SorA whereas at 10 nM protein level was reduced by ~50% as determined by
20 Western blot and immunofluorescence (Fig. 5A-D). By using these conditions we found
21 that SorA treatment profoundly reduced both DMV size (Fig. 5H) and number (Fig. 5I),
22 especially when using 10 nM SorA. Although at this concentration HCV protein amount
23 was reduced, the degree of this reduction was much lower as compared to the very
24 pronounced inhibition of DMV formation. In conclusion, these results provide strong

1 evidence that SorA inhibits HCV replication, at least in part, by interfering with
2 formation of the membranous replication factory.

3

4 *SorA inhibits HCV replication in persistently infected Huh7/Scr cells and in a stable*
5 *replicon cell line*

6

7 To exclude the possibility that SorA inhibits HCV RNA replication only by inhibition
8 of *de novo* replication complexes we sought to test the efficacy of SorA in a persistently
9 infected Huh7/Scr cells. For this, we established over a period of four weeks cultures of
10 Huh7/Scr cells persistently infected with Jc1 (>95% positive for NS5A by
11 immunofluorescence, data not shown) and treated for 10 days with SorA or with the
12 controls TOFA or VX-950. We observed that SorA reduced HCV RNA levels by ~80%
13 and ~95% for the concentrations 1 and 10 μM , respectively (Fig. 6A). The EC_{50} for
14 SorA was 0.152 μM , while for the controls TOFA and VX-950 EC_{50} values it was
15 0.976 and 0.110 μM , respectively. The resulting HCV RNA reduction was confirmed at
16 the protein level by detection of NS5A protein by immunofluorescence (Fig. 6B). To
17 further corroborate our results, we treated with SorA or controls a stable replicon cell
18 line of Huh7 cells harboring the LucUbineo JFH1 replicon [42]. As shown in
19 Supplementary Fig. 1C, SorA reduced HCV replication in this cell line as deduced by
20 the luciferase activity.

21

22 *SorA presents high barrier to resistance in cell culture*

23

24 To explore the barrier to resistance of SorA in cell culture, Huh7/Scr cells were infected
25 with the Jc1 virus (at an MOI 1 $\text{TCID}_{50}/\text{cell}$, corresponding to passage 0) and the

1 following day were treated with 100, 250 or 500 nM SorA (representing $\sim 1x$ EC₉₀,
2 $\sim 2.5x$ EC₉₀ and $\sim 5x$ EC₉₀, respectively). Cells were passaged every 2-3 days and at each
3 passage cell culture supernatant was frozen for further resistant viruses' analyses. The
4 VX-950 inhibitor was used in parallel as a control at the same concentrations. As shown
5 in Fig. 7, SorA presented high barrier to resistance for at least 6 cell culture passages
6 and 3 supernatant passages (data not shown, in total 25 days). In contrary, VX-950
7 resistant viruses appeared as early as 3 passages post infection for the 100 nM
8 concentration and 5 passages for the 500 nM concentration.

9

10 *SorA analogues inhibit the Luc-Jc1 virus*

11

12 Although we demonstrated that SorA potently inhibited HCV in cell culture, its limited
13 water solubility (Sol) was reported to hamper its *in vivo* efficacy [17]. To address this
14 obstacle, we explored the structural determinants of the anti-HCV activity of SorA in
15 order to derive analogs with higher solubility without activity loss. To this end, a series
16 of SorA analogues obtained from fermentation and total synthesis has been tested for
17 their anti-HCV activity by using the Luc-Jc1 virus as described above (Fig. 8 and
18 Supplementary Fig. 3). Various structural alterations of SorA were tolerated in terms of
19 activity, in particular at the pyran ring: a derivatization of the alcohol function at C-5
20 with a long, solubilizing polyethylene-glycol chain (as in Sor-S1036), led to an
21 approximately equipotent compound with an EC₅₀ of 1.3 nM and Sol: ~ 2.0 mg/ml (vs.
22 EC₅₀: 0.7 nM and Sol: ~ 0.2 mg/ml for SorA). Likewise, the methyl substituent at C-6
23 can be replaced by an ethyl group, yielding SorE1, without loss of activity. However,
24 the so-called Paleo-soraphens A and B, featured by an α , β unsaturated double bond at
25 C-2/C-3 and a lack of the pyran ring [43], were completely inactive. Also the extension

1 of the methyl group at C2 to an ethyl group (as in SorD1) was not tolerated. In the
2 northern half of the molecule, the formal reduction of the double bond of SorA at C-
3 9/C-10 led to the approximately equipotent analog SorF (EC₅₀ of 1.8 nM and Sol: ~0.2
4 mg/ml). In contrast, the demethylation of the methoxy group at C-11 was associated
5 with an at least 12-fold drop of activity, as demonstrated by SorA2β (EC₅₀: 36 nM and
6 Sol: ~0.6 mg/ml) and SorC (EC₅₀: 8.8 nM and Sol: ~0.6 mg/ml). A double
7 demethylation, as found in SorA4α, led to a sharp drop of activity (EC₅₀ of 260 nM)
8 compared to SorA. Finally, a formal hydroxylation at C14, yielding SorB1, led to a 10-
9 fold loss of activity. For all compounds, a cellular cytotoxicity >10 μM was observed,
10 thereby maintaining the very high (>1000) selectivity index of the active analogs.

11

12

13 **Discussion**

14

15 In this study we demonstrate that the *Myxobacteria*-derived polyketide natural product
16 SorA and its analogues acted as highly potent HCV replication inhibitors. SorA is a
17 nanomolar inhibitor of eukaryotic ACCs [18] and mediates its antiviral effect at least in
18 part through interfering with membranous web formation, the sites of viral genome
19 copying and amplification. These observations are remarkable for several reasons. First,
20 when cells were pre-incubated with SorA or several of its analogues, the EC₅₀ values
21 were <10 nM for the JFH1-based assays (genotype 2a), regardless of the experimental
22 system used (luciferase-carrying viruses, wild-type viruses or subgenomic replicons).
23 While this manuscript was under review, Singaravelu *et. al.*, reported an EC₅₀: 5 nM of
24 SorA in stable Huh7 cell lines harboring the Con1 subgenomic replicon (genotype 1b)
25 [44]. We confirmed this result with a similar cell line harboring Con1 subgenomic

1 replicon as well (Supplementary Fig. 1B). Furthermore, there was no apparent toxicity
2 up to 10 μ M SorA. Notably, these values are comparable to those estimated for the
3 Food and Drug Administration (FDA)-approved protease inhibitor VX-950. In contrast,
4 the commercial ACC inhibitor TOFA has shown an EC_{50} in the range of 70-976 nM,
5 depending on the experimental system used. Second, given the genetic stability of the
6 host, the development of a broad-spectrum antivirals would have the advantage of
7 rendering selection of drug resistant virus mutants less likely, a major problem of
8 conventional drugs that target viral proteins [7]. Indeed, targeting a cellular host factor,
9 ACC in this case, instead of a viral protein is an attractive strategy for anti-HCV
10 intervention because this type of anti-viral drug, as shown in Fig.7, presents high
11 barriers to resistance development. Third, SorA and F have previously been shown to
12 inhibit HIV *in vitro* [13]. Thus, SorA and analogues represent very attractive candidates
13 to be developed into single broad-spectrum antiviral agents for treating HCV/HIV co-
14 infections.

15

16 SorA is a specific inhibitor of the first committed step of lipid biosynthesis catalyzed by
17 ACCs. In the presence of SorA, HCV replication was partially restored when myristic,
18 lauric or palmitic acids were added to the media, the latter having the highest effect.
19 Palmitic acid, during fatty acid biosynthesis from acetyl-CoA, is the first fatty acid to be
20 produced and the most common fatty acid in animals. In agreement with a SorA anti-
21 HCV activity mediated by lipid alteration, EM studies show that in cells transfected
22 with infectious HCV RNA, SorA significantly reduced the size and number of
23 endoplasmic reticulum-derived DMVs, the main constituents of the membranous web.
24 In the heterologous expression-based system we observed DMV inhibition only in
25 numbers. This might be due to the higher expression level of HCV proteins achieved in

1 that system or to a coupling of inhibition of web formation by SorA with HCV RNA
2 replication. These results emphasize the need to use systems that mimic HCV infections
3 (i.e. replication-competent viruses).

4

5 Several SorA analogues were obtained from fermentation and total synthesis. Our
6 results show that various structural alterations of SorA are tolerated in terms of activity.

7 It was observed that the removal of hydroxy or methoxy groups at C-5, C-4 or C5/C-3
8 was associated with 5-fold, 10-fold and 300-fold drops of potency, respectively, while

9 few substitutions at C-5 (e.g. by formyl) led to equipotent compounds [45-48]. An
10 elongation at C-11 through ester or ether groups led to improved activities for some

11 analogues, while all changes at C-12 or C-17 were associated with reduced activities.

12 Our data provide first insights to structure activity relationships in a human cellular
13 assay, suggesting that positions C-5 or the northern hemisphere (C-9 to C-10) are well-

14 suited for the optimization of the pharmacologic and pharmacokinetic properties of

15 SorA through structural modifications. The lack of activity of the Paleo-soraphens may
16 explain why the costly biosynthesis of these variants has been eliminated by evolution.

17 The solubility of SorA (0.2 mg/ml) was improved by replacing the methoxy group by a
18 more polar hydroxyl group at C11, as demonstrated by the solubility of both derivatives

19 SorA2 β and SorC (0.6 mg/mL). However, this enhancement was associated with a drop
20 of activity. In contrast, the derivative Sor-S1036 exhibited a higher aqueous solubility

21 (2.0 mg/ml) while maintaining potency. Thus, it is possible to improve the
22 physicochemical properties of SorA without loss of activity. Consequently, Sor-S1036

23 has demonstrated higher efficacy *in vivo* in a mouse model of EAE than SorA [17] .

24 However, since the long solubilizing chain introduced in Sor-S1036 hampered the

1 permeability of the compound and prevented an oral administration, the search for
2 Soraphen analogs with optimized pharmacological properties deserves continuation.

3
4 In conclusion, a new nanomolar inhibitor of HCV is described that blocks a cellular host
5 factor with high affinity and mediates its antiviral effect via alterations of the lipid
6 requirements of viral replication. Due to its interesting overlapping activity of inhibiting
7 also HIV SorA may present a prototype of a new class of broad-spectrum antiviral
8 compounds acting via lipid metabolic changes.

9 10 **ACKNOWLEDGEMENTS**

11 We thank Heinrich Steinmetz and Dr. Rolf Jansen for the natural Soraphen analogs. The
12 authors are supported by grants BFU2013-44629-R (to JD, GK and GPV), SAF2013-
13 46077-R (to AM and JM), both from the Spanish Ministry of Economy and
14 Competitiveness and FEDER, and from the German Centre for Infection Research
15 (DZIF, to MB and RM).

16 17 18 **FIGURE LEGENDS**

19
20 **Figure 1. Soraphen A inhibits HCV genotype 2a infection in Huh7/Scr cells and**
21 **PHHs.** (A) SorA structure. (B) Anti-HCV activity and cell viability, using Huh7/Scr
22 cells infected with Luc-Jc1 reporter virus (depicted above) and treated with increasing
23 concentrations of SorA, TOFA or VX-950. Data are expressed as mean values of three
24 independent experiments (\pm SEM). (C) Anti-HCV activity and viability on Huh7/Scr
25 cells infected with Jc1 virus depicted above and treated with increasing concentrations

1 of SorA or 2'-C-Met. Data were plotted as percentage relative to the DMSO control for
2 both infectivity and cell viability. Data are expressed as mean values of four
3 measurements of two biological replicates (\pm SEM). (D) Anti-HCV activity of SorA in
4 PHHs. The inhibition of infection was assessed by an endpoint dilution assay (TCID₅₀)
5 24h and 48h post-infection and is expressed as the percentage of inhibition relative to
6 DMSO-treated cells. Data are expressed as mean values of four measurements of two
7 biological replicates (\pm SEM) and from a single experiment representative of three
8 independent PHHs donors.

9

10 **Figure 2. Soraphen A inhibits HCV replication.** (A) Anti-viral activity of the
11 indicated compounds using subgenomic HCV replicons (SGR-JFH1, depicted above).
12 (B) Anti-HCVpp activity of SorA or dasatinib and cell viability using Huh7/Scr cells
13 infected with HCVpp bearing J6 glycoproteins. Results were plotted as percentage
14 relative to the DMSO control for both infectivity and cell viability. (C) Effect of SorA,
15 TOFA or VX-950 on HCV translation. Results were plotted as percentage relative to the
16 DMSO control and are expressed as mean RLU values of four measurements of two
17 biological replicates (\pm SEM).

18

19 **Figure 3. Fatty acids add-back rescues HCV replication in Soraphen A treated**
20 **Huh7/Scr cells.** The indicated fatty acids or lipids at final concentration of 10 (white
21 bars) or 50 μ M (black bars) were added simultaneously to cells infected with Luc-Jc1
22 and treated with SorA (10 nM). All data were plotted as percentage relative to solvent
23 control for both (A) infectivity and (B) cell viability. Data are expressed as mean values
24 of four measurements of two biological replicates (\pm SEM).

25

1 **Figure 4. Effect of Soraphen A on the formation of HCV-induced DMVs in an**
2 **expression-based system.** (A) Western blot analysis of NS5A abundance in cells
3 expressing the HCV non-structural proteins (NS3-5B) treated with increasing
4 concentrations of SorA up to 100nM. (B-E) Representative IF and EM images of NS3-
5 5B expressing cells. Cells were treated with (B, D) solvent only (DMSO) or (C, E)
6 SorA (100 nM). (F) Comparison of DMVs diameter in DMSO vs. SorA treated cells.
7 (G) Comparison of DMVs numbers in DMSO vs. SorA treated cells.

8

9 **Figure 5. Effect of Soraphen A on the formation of HCV-induced DMVs in a**
10 **replication system.** (A) Western blot analysis of NS5A expression in cells
11 electroporated with Jc1 RNA and treated with increasing concentrations of SorA.
12 Numbers below indicate amount of NS5A normalized to the levels in DMSO-treated
13 samples (set to 100%). (B - G) Representative IF and EM images of Jc1-transfected
14 cells (B, E) treated with DMSO only, (C, F) 1 nM SorA or (D, G) 10 nM SorA. (H)
15 Comparison of DMVs size in Jc1 RNA-transfected cells treated with DMSO or SorA (1
16 or 10 nM). (I) Quantification DMVs number per μm^2 in cells described in H.

17

18 **Figure 6. Soraphen A inhibits HCV replication in persistently infected Huh7/Scr**
19 **cells.** (A) Anti-HCV activity using Huh7/Scr cells persistently infected with Jc1 viruses
20 and treated with SorA, TOFA or VX-950 at the indicated concentrations. All data were
21 plotted as percentage relative to the DMSO control and present the HCV RNA values as
22 measured by RT-qPCR. Data are expressed as mean values of four measurements of
23 two biological replicates (\pm SEM). (B) Immunofluorescence analysis of NS5A protein
24 (green) in persistently infected cells treated with SorA (10 μM), TOFA (10 μM) or VX-
25 950 (10 μM). Cell nuclei were counterstained with DAPI (blue), magnification 63x.

1

2 **Figure 7. Soraphen A presents high barrier to resistance *in vitro*.** The determination
3 of resistant Jc1 viruses to SorA or VX-950 (at the indicated concentrations) in
4 Huh7/Scr cells was assessed for 6 cell passages by a TCID₅₀ assay of the supernatant
5 and is expressed plotted in relation to DMSO-treated cells.

6

7 **Figure 8.** Structures and antiviral activities, expressed as EC₅₀, of SorA and SorA
8 analogues.

9

10 **REFERENCES**

11

12 [1] Barreiro P, Fernandez-Montero JV, de Mendoza C, Labarga P, Soriano V.
13 Towards hepatitis C eradication from the HIV-infected population. *Antiviral research*
14 2014;105:1-7.

15 [2] Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and
16 management. *Nature reviews Gastroenterology & hepatology* 2014;11:362-371.

17 [3] Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. *The Lancet*
18 2015;doi:10.1016/S0140-6736(14)62401-6.

19 [4] Bichoupan K, Dieterich DT, Martel-Laferriere V. HIV-hepatitis C virus co-
20 infection in the era of direct-acting antivirals. *Current HIV/AIDS reports* 2014;11:241-
21 249.

22 [5] Lange CM, Jacobson IM, Rice CM, Zeuzem S. Emerging therapies for the
23 treatment of hepatitis C. *EMBO molecular medicine* 2014;6:4-15.

24 [6] Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all?
25 *Nature reviews Drug discovery* 2013;12:595-610.

- 1 [7] De Clercq E. The design of drugs for HIV and HCV. *Nature reviews Drug*
2 *discovery* 2007;6:1001-1018.
- 3 [8] Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y, et al. Broad-
4 spectrum inhibition of retroviral and filoviral particle release by tetherin. *Journal of*
5 *virology* 2009;83:1837-1844.
- 6 [9] Wolf MC, Freiberg AN, Zhang T, Akyol-Ataman Z, Grock A, Hong PW, et al.
7 A broad-spectrum antiviral targeting entry of enveloped viruses. *Proceedings of the*
8 *National Academy of Sciences of the United States of America* 2010;107:3157-3162.
- 9 [10] Alvisi G, Madan V, Bartenschlager R. Hepatitis C virus and host cell lipids: an
10 intimate connection. *RNA biology* 2011;8:258-269.
- 11 [11] Alfadhli A, Barklis E. The roles of lipids and nucleic acids in HIV-1 assembly.
12 *Frontiers in microbiology* 2014;5:253.
- 13 [12] Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova
14 N, et al. Human immunodeficiency virus impairs reverse cholesterol transport from
15 macrophages. *PLoS biology* 2006;4:e365.
- 16 [13] Martinez JP, Hinkelmann B, Fleta-Soriano E, Steinmetz H, Jansen R, Diez J, et
17 al. Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step
18 infectivity assay. *Microbial cell factories* 2013;12:85.
- 19 [14] Gerth K, Bedorf N, Irschik H, Hofle G, Reichenbach H. The soraphens: a family
20 of novel antifungal compounds from *Sorangium cellulosum* (Myxobacteria). I.
21 Soraphen A1 alpha: fermentation, isolation, biological properties. *The Journal of*
22 *antibiotics* 1994;47:23-31.
- 23 [15] Corominas-Faja B, Cuyas E, Gumuzio J, Bosch-Barrera J, Leis O, Martin AG, et
24 al. Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of
25 cancer stem cells. *Oncotarget* 2014;5:8306-8316.

- 1 [16] Schreurs M, Van Dijk TH, Gerding A, Havinga R, Reijngoud DJ, Kuipers F.
2 Soraphen, an inhibitor of the acetyl-CoA carboxylase system, improves peripheral
3 insulin sensitivity in mice fed a high-fat diet. *Diabetes, Obesity and Metabolism*
4 2009;11:987-991.
- 5 [17] Berod L, Friedrich C, Nandan A, Freitag J, Hagemann S, Harmrolfs K, et al. De
6 novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells.
7 *Nature medicine* 2014;20:1327-1333.
- 8 [18] Shen Y, Volrath SL, Weatherly SC, Elich TD, Tong L. A mechanism for the
9 potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a
10 macrocyclic polyketide natural product. *Molecular cell* 2004;16:881-891.
- 11 [19] Abu-Elheiga L, Jayakumar A, Baldini A, Chirala SS, Wakil SJ. Human acetyl-
12 CoA carboxylase: characterization, molecular cloning, and evidence for two isoforms.
13 *Proceedings of the National Academy of Sciences of the United States of America*
14 1995;92:4011-4015.
- 15 [20] Jump DB, Torres-Gonzalez M, Olson LK. Soraphen A, an inhibitor of acetyl
16 CoA carboxylase activity, interferes with fatty acid elongation. *Biochemical*
17 *pharmacology* 2011;81:649-660.
- 18 [21] Koutsoudakis G, Perez-del-Pulgar S, Coto-Llerena M, Gonzalez P, Dragun J,
19 Mensa L, et al. Cell culture replication of a genotype 1b hepatitis C virus isolate cloned
20 from a patient who underwent liver transplantation. *PloS one* 2011;6:e23587.
- 21 [22] Berger C, Romero-Brey I, Radujkovic D, Terreux R, Zayas M, Paul D, et al.
22 Daclatasvir-Like Inhibitors of NS5A Block Early Biogenesis of Hepatitis C Virus-
23 Induced Membranous Replication Factories, Independent of RNA Replication.
24 *Gastroenterology* 2014; DOI 10.1053/j.gastro.2014.07.019.

- 1 [23] Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust
2 hepatitis C virus infection in vitro. Proceedings of the National Academy of Sciences of
3 the United States of America 2005;102:9294-9299.
- 4 [24] Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al.
5 Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-626.
- 6 [25] Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al.
7 Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.
8 Nature medicine 2005;11:791-796.
- 9 [26] Friebe P, Boudet J, Simorre JP, Bartenschlager R. Kissing-loop interaction in the
10 3' end of the hepatitis C virus genome essential for RNA replication. Journal of virology
11 2005;79:380-392.
- 12 [27] Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E,
13 et al. Construction and characterization of infectious intragenotypic and intergenotypic
14 hepatitis C virus chimeras. Proceedings of the National Academy of Sciences of the
15 United States of America 2006;103:7408-7413.
- 16 [28] Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, et
17 al. Characterization of the early steps of hepatitis C virus infection by using luciferase
18 reporter viruses. Journal of virology 2006;80:5308-5320.
- 19 [29] Niles AL, Moravec RA, Eric Hesselberth P, Scurria MA, Daily WJ, Riss TL. A
20 homogeneous assay to measure live and dead cells in the same sample by detecting
21 different protease markers. Analytical biochemistry 2007;366:197-206.
- 22 [30] Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host
23 geranylgeranylation and fatty acids. Proceedings of the National Academy of Sciences
24 of the United States of America 2005;102:2561-2566.

- 1 [31] Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel,
2 covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. *Infectious*
3 *disorders drug targets* 2006;6:3-16.
- 4 [32] Carroll SS, Tomassini JE, Bosserman M, Getty K, Stahlhut MW, Eldrup AB, et
5 al. Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs.
6 *The Journal of biological chemistry* 2003;278:11979-11984.
- 7 [33] Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, et al.
8 Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon.
9 *Gastroenterology* 2003;125:1808-1817.
- 10 [34] Frese M, Barth K, Kaul A, Lohmann V, Schwärzle V, Bartenschlager R.
11 Hepatitis C virus RNA replication is resistant to tumour necrosis factor- α . *Journal of*
12 *General Virology* 2003;84:1253-1259.
- 13 [35] Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-
14 particles containing functional E1-E2 envelope protein complexes. *J Exp Med*
15 2003;197:633-642.
- 16 [36] Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, et al. EGFR and
17 EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral
18 therapy. *Nature medicine* 2011;17:589-595.
- 19 [37] Yamashita T, Kaneko S, Shirota Y, Qin W, Nomura T, Kobayashi K, et al.
20 RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus
21 NS5B protein truncated at the C-terminal region. *The Journal of biological chemistry*
22 1998;273:15479-15486.
- 23 [38] Tong L. Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and
24 attractive target for drug discovery. *Cellular and molecular life sciences : CMLS*
25 2005;62:1784-1803.

- 1 [39] Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K, et al.
2 Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring
3 subgenomic replicons. *Journal of virology* 2003;77:5487-5492.
- 4 [40] Romero-Brey I, Merz A, Chiramel A, Lee JY, Chlanda P, Haselman U, et al.
5 Three-dimensional architecture and biogenesis of membrane structures associated with
6 hepatitis C virus replication. *PLoS pathogens* 2012;8:e1003056.
- 7 [41] Paul D, Hoppe S, Saher G, Krijnse-Locker J, Bartenschlager R. Morphological
8 and biochemical characterization of the membranous hepatitis C virus replication
9 compartment. *Journal of virology* 2013;87:10612-10627.
- 10 [42] Jo J, Aichele U, Kersting N, Klein R, Aichele P, Bisse E, et al. Analysis of
11 CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel
12 immunological model. *Gastroenterology* 2009;136:1391-1401.
- 13 [43] Lu HH, Raja A, Franke R, Landsberg D, Sasse F, Kalesse M. Synthesis and
14 biological evaluation of paleo-soraphens. *Angewandte Chemie* 2013;52:13549-13552.
- 15 [44] Singaravelu R, Desrochers GF, Srinivasan P, O'Hara S, Lyn RK, Müller R, et al.
16 Soraphen A: A Probe for Investigating the Role of de Novo Lipogenesis during Viral
17 Infection. *ACS Infectious Diseases* 2015;DOI:10.1021/acsinfecdis.5b00019.
- 18 [45] Böhlendorf B, Höfle G, Kiffe M, C. O'Sullivan A, Schummer D, Sutter M.
19 Chemistry and Fungicidal Activity of Soraphen A1 α Derivatives. *Phytochemicals for*
20 *Pest Control: American Chemical Society; 1997. p. 249-266.*
- 21 [46] Kiffe M, Schummer D, Höfle G. Antibiotics from Gliding Bacteria, LXXIX. –
22 Chemical Modification of the Antifungal Macrolide Soraphen A1 α : Deoxygenation in
23 the South-East Ring Segment. *Liebigs Annalen* 1997;1997:245-252.

- 1 [47] Schummer D, Jahn T, Höfle G. Antibiotics from gliding bacteria, LXV.
2 Synthesis of soraphen analogues by substitution of the phenyl-C-17 ring segment of
3 soraphen A1 α . Liebigs Annalen 1995;1995:803-816.
- 4 [48] Bedarf ND, Böhlendorf B, Forche ED, Gerth KD, Höfle GPD, Irschik HD, et al.
5 Mikrobiologisches Verfahren zur Herstellung agrarchemisch verwendbarer
6 mikrobizider makrozyklischer Lactonderivate. Google Patents; 1990.
- 7
8